OKT3 escalating dose regimens provide effective therapy for renal allograft rejection

Clinical Transplantation

Volumn 10, Issue 4, 1996, Pages 389-395

  Woodle, E Steve ^a   Bruce, David S ^a   Josephson, Michelle ^a   Cronin, David ^a   Newell, Kenneth A ^a   Michael Millis, J ^a   Piper, James B ^a   O'Laughlin, Rita ^a   Thistlethwaite Jr , J Richard ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anti CD3 antibody; Kidney transplant; OKT3; Rejection

Indexed keywords

CD3 ANTIGEN; CD5 ANTIGEN; CORTICOSTEROID; CREATININE; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTHRALGIA; ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; MALE; PRIORITY JOURNAL; VIREMIA;

COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; PILOT PROJECTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029740055     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. COSIMI AB, BURTON RC, COLVIN RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981: 32: 535.
2. ORTHO MULTI-CENTER TRANSPLANT STUDY GROUP. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313: 357.
3. GILBERT EM, DEWITT CW, EISWIRTH CC, RENLUND DG, MENLOVE RL. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 1987: 82: 202.
4. COLONNA JO, GOLDSTEIN LI, BREMS JJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987: 122: 1120.
5. COSIMI AB, CHO SI, DELMONICO FL, KAPLAN MM, ROHRER RJ, JENKINS RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987: 43: 91.
6. NORMAN DJ, KIMBALL JA, BENNETT WM, et al. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant Int 1994: 7: 356.
7. PARLEVLIET KJ, TEN BERGE RJ, RAASVELD MH, SURACHNO J, WILMINK JM, SCHELLEKENS PT. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transpl 1994: 9: 698.
8. ALONSO-PULPON L, SERRANO FIZ S, RUBIO JA, et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transpl 1995: 14: 136.
9. ABRAMOWICZ D, PRADIER O, MARCHANT A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992: 339: 777.
10. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
11. HIRSCH R, ECKHAUS M, AUCHINCLOSS H, SACHS DH, BLUESTONE JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988: 140: 3766.
12. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation1990: 49: 1117.
13. ELLENHORN JDI, WOODLE ES, GHOBRIAL I, THISTLETHWAITE JR, BLUESTONE JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990: 50: 608.
14. KERR PG, ATKINS RC. The effects of OKT3 therapy on infiltrating lymphocytes in rejecting renal allografts. Transplantation 1989: 48: 33.
15. CAILLAT-ZUCMAN S, BLUMENFELD N, LEGENDRE C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990:49: 156.
16. THISTLETHWAITE JR, STUART JK, MAYES JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988: 11: 112.
17. WOODLE ES, AND THISTLETHWAITE JR FOR THE FK 506 MULTICENTER FK 506 KIDNEY TRANSPLANT RESCUE STUDY GROUP. A multicenter trial of FK 506 (Tacrolimus) rescue therapy in renal transplantation. Kidney Int (in press).
18. WOODLE ES, JOSEPHSON M, NEWELL K, et al. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transpl 1996: 10: 323.
19. JORDAN ML, SHAPIRO R, VIVAS CA, et al. FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994: 57: 860.
20. + T cells. Transplantation 1996: 61: 798.